Assay Protocol
Neutralizing antibodies (NeutraABs) are a shining star in the field of life sciences, holding limitless potential in life science research and biopharmaceuticals, particularly playing a crucial role in viral infections and immunotherapy. Creative Biolabs is honored to be a leader in NeutraAB research. We deeply understand the importance of NeutraABs in life science research and medicine.
Comprehensive Assay Protocol Support
Based on our Recombinant Antibody Production Platform, which is developed to produce antibodies with specific functions and specificities rapidly and efficiently, we are dedicated to providing customers with high-quality NeutraAB products and customized services. Considering that each customer's research projects and needs vary, and to ensure they obtain high-quality NeutraABs, we introduce the most comprehensive set of assays based NeutraABs. These assays aim to help comprehensively evaluate and validate the specificity and neutralizing activity of antibodies.
8 Micro-neutralization (MN) Assay Protocol
Determine the inhibitory capacity of NeutraABs against viruses.
9 Hemagglutination Inhibition (HI) Assay
Protocol
Determine the inhibition of virus hemagglutination by NeutraABs.
10 Plaque Reduction Neutralization
Test (PRNT) Protocol
Measure the inhibitory capacity of NeutraABs against viral infection.
Through transparent and standardized experimental procedures, we showcase our expertise and experience in NeutraAB research and customization. Customers can gain insights into our excellent techniques in antibody identification and functional assessment, as well as our strict quality control measures. At the same time, we aim to provide support for customers' research projects by offering the methods and steps required.
Expertise
Rich experience
Stringent product quality control
Rich Providing methodological support for customers' research
Creative Biolabs sincerely invites you to contact us. Our professional team is committed to providing high-specificity NeutraAB products and the best NeutraAB solutions for various research fields. Whether you are in academia or industry, we will tailor the most suitable products and services according to your needs. Let us work together to create a brilliant future for NeutraABs!
Hot Products
| Cat | Product Name | Target | Target Species | Application | Featured Application |
|---|---|---|---|---|---|
| V3S-0622-YC39 | Anti-B5 Env Neutralizing Antibody (V3S-0622-YC39) | B5 Env | Vaccinia Virus (VACV) | ELISA; WB; Neut; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0622-YC523 | Anti-TFRC (ECD domain) Neutralizing Antibody (V3S-0622-YC523) | TFRC | Mouse | IHC; FC; WB; FuncS | |
| V3S-0622-YC1236 | Anti-CD2 Neutralizing Antibody (V3S-0622-YC1236) | CD2 | Human | ELISA; IP; FC; FuncS; Neut; IF; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC1243 | Anti-CD24 Neutralizing Antibody (V3S-0622-YC1243) | CD24 | Human | FuncS | |
| V3S-0622-YC1300 | Anti-CD3E Neutralizing Antibody (V3S-0622-YC1300) | CD3E | Human | FC; IP; ELISA; Neut; FuncS; IF; WB | Neutralizing/Blocking Antibodies |
| V3S-0622-YC1939 | Anti-IL6 Neutralizing Antibody (V3S-0622-YC1939) | IL6 | Human | FuncS | |
| V3S-0622-YC1943 | Anti-IL6 Neutralizing Antibody (V3S-0622-YC1943) | IL6 | Human | FC; IP; ELISA; Neut; FuncS; IF; WB | Neutralizing/Blocking Antibodies |
| V3S-0622-YC1944 | Anti-IL6R Neutralizing Antibody (V3S-0622-YC1944) | IL6R | Human | ELISA; FC; IP; FuncS; IF; Neut; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC1951 | Anti-INHBB Neutralizing Antibody (V3S-0622-YC1951) | INHBB | Human, <em>Xenopus laevis</em> | FuncS | |
| V3S-0622-YC2110 | Anti-LTA Neutralizing Antibody (V3S-0622-YC2110) | LTA | Human | Neut; ELISA; IF; IP; FuncS; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC2177 | Recombinant Anti-MICA (ECD domain) Antibody (V3S-0622-YC2177) | MICA | Human | ELISA; FC | |
| V3S-0622-YC2216 | Anti-MS4A1 Neutralizing Antibody (V3S-0622-YC2216) | MS4A1 | Human | IF; IP; Neut; FuncS; ELISA; FC; WB | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4319 | Anti-CD33 Neutralizing Antibody (V3S-0622-YC4319) | CD33 | Human | IF; IP; Neut; FuncS; ELISA; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4322 | Anti-CD3D Neutralizing Antibody (V3S-0622-YC4322) | CD3D | Human | Neut; ELISA; IF; IP; FuncS; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4330 | Anti-CD4 Neutralizing Antibody (V3S-0622-YC4330) | CD4 | Human | FuncS; IF; Neut; ELISA; FC; IP; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4333 | Anti-CD4 (ECD domain) Neutralizing Antibody (V3S-0622-YC4333) | CD4 | Human | WB; ELISA; FC; IP; FuncS; IF; Neut | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4344 | Anti-CD70 Neutralizing Antibody (V3S-0622-YC4344) | CD70 | Human | ELISA; FC; IP; FuncS; IF; Neut; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4410 | Anti-DKK1 Neutralizing Antibody (V3S-0622-YC4410) | DKK1 | Human | FuncS | |
| V3S-0622-YC4450 | Anti-ERBB3 Neutralizing Antibody (V3S-0622-YC4450) | ERBB3 | Human | IP; IF; FuncS; FC; Neut; ELISA; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4451 | Anti-ERBB3 Neutralizing Antibody (V3S-0622-YC4451) | ERBB3 | Human | IF; IP; Neut; FuncS; ELISA; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4458 | Anti-FCER2 Neutralizing Antibody (V3S-0622-YC4458) | FCER2 | Human | WB; Neut; ELISA; IF; IP; FuncS; FC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4467 | Anti-FGFR2 Neutralizing Antibody (V3S-0622-YC4467) | FGFR2 | Human | FuncS | |
| V3S-0622-YC4468 | Anti-FLT1 (Ig-like loop 1-5) Neutralizing Antibody (V3S-0622-YC4468) | FLT1 | Human | IF; IP; Neut; FuncS; ELISA; FC; WB | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4469 | Anti-FLT3 Neutralizing Antibody (V3S-0622-YC4469) | FLT3 | Human | FuncS | |
| V3S-0622-YC4527 | Anti-GPC3 Neutralizing Antibody (V3S-0622-YC4527) | GPC3 | Human | FuncS; IF; Neut; ELISA; FC; IP; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4570 | Anti-IgE Fc Neutralizing Antibody (V3S-0622-YC4570) | IgE Fc | Human | IF; IP; Neut; FuncS; ELISA; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4575 | Anti-IGF1R Neutralizing Antibody (V3S-0622-YC4575) | IGF1R | Human | FC; IP; ELISA; Neut; FuncS; IF; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4585 | Anti-IL13 Neutralizing Antibody (V3S-0622-YC4585) | IL13 | Human | FC; IP; ELISA; Neut; FuncS; IF; IHC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4771 | Anti-IL6 Neutralizing Antibody (V3S-0622-YC4771) | IL6 | Human | IF; IP; Neut; FuncS; ELISA; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4835 | Recombinant Anti-αvβ8 Antibody (V3S-0622-YC4835) | αvβ8 | Human | FC | |
| V3S-0622-YC4858 | Anti-ITGAV Neutralizing Antibody (V3S-0622-YC4858) | ITGAV | Human | ELISA; IP; FC; FuncS; IF; Neut | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4990 | Anti-MS4A1 Neutralizing Antibody (V3S-0622-YC4990) | MS4A1 | Human | IF; IP; Neut; FuncS; ELISA; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC4991 | Anti-MS4A1 Neutralizing Antibody (V3S-0622-YC4991) | MS4A1 | Human | ELISA; IP; FC; FuncS; Neut; IF; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5028 | Recombinant Anti-MUC1 Antibody (V3S-0622-YC5028) | MUC1 | Human | ELISA; IHC | |
| V3S-0622-YC5072 | Anti-NCAM1 Neutralizing Antibody (V3S-0622-YC5072) | NCAM1 | Human | ELISA; FC; IP; FuncS; IF; Neut; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5128 | Anti-NOTCH2 Neutralizing Antibody (V3S-0622-YC5128) | NOTCH2 | Human | IF; IP; Neut; FuncS; ELISA; FC; WB | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5137 | Recombinant Anti-NOTCH3 Antibody (V3S-0622-YC5137) | NOTCH3 | Human | ELISA | |
| V3S-0622-YC5167 | Anti-NRP1 Neutralizing Antibody (V3S-0622-YC5167) | NRP1 | Human | IP; IF; FuncS; FC; Neut; ELISA; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5179 | Anti-PCSK9 Neutralizing Antibody (V3S-0622-YC5179) | PCSK9 | Human | FC; IP; ELISA; Neut; FuncS; IF; IHC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5183 | Anti-PDCD1 Neutralizing Antibody (V3S-0622-YC5183) | PDCD1 | Human | IF; IP; Neut; FuncS; ELISA; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5232 | Anti-PVRL4 Neutralizing Antibody (V3S-0622-YC5232) | PVRL4 | Human | ELISA; Neut; IF; IP; FC; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5257 | Anti-RSPO1 (aa 31-263) Neutralizing Antibody (V3S-0622-YC5257) | RSPO1 | Human | WB; ELISA; Block; IP | Neutralizing Antibodies |
| V3S-0622-YC5270 | Anti-RSV F Neutralizing Antibody (V3S-0622-YC5270) | RSV F | Rous Sarcoma Virus (RSV) | IF; IP; Neut; FuncS; ELISA; FC; WB | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5352 | Anti-SIGLEC15 Neutralizing Antibody (V3S-0622-YC5352) | SIGLEC15 | Human | FuncS | |
| V3S-0622-YC5357 | Anti-SIGLEC15 Neutralizing Antibody (V3S-0622-YC5357) | SIGLEC15 | Human | ELISA; FC; Block | Neutralizing Antibodies |
| V3S-0622-YC5664 | Anti-TNFRSF10B Neutralizing Antibody (V3S-0622-YC5664) | TNFRSF10B | Human | ELISA; IP; FC; FuncS; Neut; IF; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5673 | Anti-TNFRSF8 Neutralizing Antibody (V3S-0622-YC5673) | TNFRSF8 | Human | Neut; ELISA; IF; IP; FuncS; FC; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5675 | Anti-TNFRSF9 (ECD domain) Neutralizing Antibody (V3S-0622-YC5675) | TNFRSF9 | Human | ELISA; FC; IP; FuncS; IF; Neut; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5690 | Anti-TNFSF4 Neutralizing Antibody (V3S-0622-YC5690) | TNFSF4 | Human | ELISA; FC; IP; FuncS; IF; Neut; ICC | Neutralizing/Blocking Antibodies |
| V3S-0622-YC5696 | Anti-VEGFA Neutralizing Antibody (V3S-0622-YC5696) | VEGFA | Human | WB; FC; IP; ELISA; Neut; FuncS; IF | Neutralizing/Blocking Antibodies |
| V3S-0522-YC487 | Anti-ANGPTL4 Neutralizing Antibody (V3S-0522-YC487) | ANGPTL4 | Human, Mouse | ELISA; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC556 | Anti-FLT3 (domain 5) Neutralizing Antibody (V3S-0522-YC556) | FLT3 | Human | ELISA; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC721 | Recombinant Anti-MICA / MICB Antibody (V3S-0522-YC721) | MICA / MICB | Human | ELISA | |
| V3S-0522-YC864 | Anti-IAV HA Neutralizing Antibody (V3S-0522-YC864) | IAV HA | Influenzavirus A (IAV) | ELISA; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC931 | Anti-C5 (aa 20-124) Neutralizing Antibody (V3S-0522-YC931) | C5 | Human, Monkey | ELISA; WB; FC; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC1206 | Anti-TSLP Neutralizing Antibody (V3S-0522-YC1206) | TSLP | Human, Monkey | ELISA; FC; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC1246 | Recombinant Anti-PLAUR Antibody (V3S-0522-YC1246) | PLAUR | Human | ELISA; FC; WB; IP | |
| V3S-0522-YC1416 | Anti-CD274 Neutralizing Antibody (V3S-0522-YC1416) | CD274 | Human | ELISA; IHC; FC; IP; IF; Block | Neutralizing Antibodies |
| V3S-0522-YC1963 | Recombinant Anti-TNFRSF8 Antibody (V3S-0522-YC1963) | TNFRSF8 | Human | FC; Cyt; FuncS | |
| V3S-0522-YC2117 | Anti-TGFB1 Neutralizing Antibody (V3S-0522-YC2117) | TGFB1 | Human, Rat, Mouse | IHC; Neut; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0522-YC2244 | Anti-HAVCR2 Neutralizing Antibody (V3S-0522-YC2244) | HAVCR2 | Human | Block; FuncS | Neutralizing Antibodies |
| V3S-0522-YC2276 | Anti-HTRA1 (protease domain) Neutralizing Antibody (V3S-0522-YC2276) | HTRA1 | Human, Mouse | ELISA; FC; Block | Neutralizing Antibodies |
| V3S-0522-YC2362 | Anti-IL17RB Neutralizing Antibody (V3S-0522-YC2362) | IL17RB | Human, Mouse | ELISA; FC; Inhib; FuncS | |
| V3S-0522-YC2365 | Anti-IL18 Neutralizing Antibody (V3S-0522-YC2365) | IL18 | Human | Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC2458 | Recombinant Anti-IL4R Antibody (V3S-0522-YC2458) | IL4R | Human, Cynomolgus | HTRF; FuncS | |
| V3S-0522-YC2473 | Anti-IL6 Neutralizing Antibody (V3S-0522-YC2473) | IL6 | Human, Cynomolgus, Mouse, Rat | ELISA; Block; FuncS | Neutralizing Antibodies |
| V3S-0522-YC2743 | Anti-SIGLEC15 (Bin 5) Neutralizing Antibody (V3S-0522-YC2743) | SIGLEC15 | Human, Mouse | FC; Block | Neutralizing Antibodies |
| V3S-0522-YC2748 | Anti-SIGLEC15 (Bin 1) Neutralizing Antibody (V3S-0522-YC2748) | SIGLEC15 | Human, Mouse | FC; Block | Neutralizing Antibodies |
| V3S-0522-YC2749 | Anti-SIGLEC15 (Bin 4) Neutralizing Antibody (V3S-0522-YC2749) | SIGLEC15 | Human, Mouse | FC; Block | Neutralizing Antibodies |
| V3S-0522-YC3137 | Anti-CD274 (aa 74-173) Neutralizing Antibody (V3S-0522-YC3137) | CD274 | Human | FC; Block; IHC; WB | Neutralizing Antibodies |
| V3S-0522-YC3165 | Recombinant Anti-CD38 Antibody (V3S-0522-YC3165) | CD38 | Human, Cynomolgus | ELISA; FC; Cyt | |
| V3S-0522-YC3178 | Anti-CD4 Neutralizing Antibody (V3S-0522-YC3178) | CD4 | Human | Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC3520 | Recombinant Anti-IAV H3 Subtype HA Antibody (V3S-0522-YC3520) | IAV H3 Subtype HA | Influenza A virus (IAV) | ELISA | |
| V3S-0522-YC3913 | Anti-SARS-CoV S Neutralizing Antibody (V3S-0522-YC3913) | SARS-CoV S | Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) | ELISA; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC3952 | Anti-RABV G Neutralizing Antibody (V3S-0522-YC3952) | RABV G | Rabies Virus (RABV) | ELISA; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC4048 | Anti-RSV Neutralizing Antibody (V3S-0522-YC4048) | RSV | Respiratory Syncytial Virus (RSV) | ELISA; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC7218 | Anti-H3N2 HA Neutralizing Antibody (V3S-0522-YC7218) | H3N2 HA | Influenzavirus A Subtype H3N2 | Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC7268 | Anti-TNFRSF17 Neutralizing Antibody (V3S-0522-YC7268) | TNFRSF17 | Human | Neut; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0522-YC7376 | Recombinant Anti-His Tag Antibody (V3S-0522-YC7376) | His Tag | WB; ELISA; FuncS | ||
| V3S-0522-YC7447 | Anti-IAV HA Neutralizing Antibody (V3S-0522-YC7447) | IAV HA | Influenza A virus (IAV) | ELISA; Neut; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0522-YC7450 | Anti-IAV HA Neutralizing Antibody (V3S-0522-YC7450) | IAV HA | Influenza A virus (IAV), Influenza B virus (IBV) | Neut; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0522-YC7451 | Anti-IAV HA Neutralizing Antibody (V3S-0522-YC7451) | IAV HA | Influenza A virus (IAV) | WB; Neut; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0522-YC7461 | Recombinant Anti-IAV HA2 Antibody (V3S-0522-YC7461) | IAV HA2 | Influenza A virus (IAV) | WB; ELISA; IHC; FuncS | |
| V3S-0522-YC7525 | Recombinant Anti-OPN Antibody (V3S-0522-YC7525) | OPN | Human | WB; ELISA; FuncS | |
| V3S-0522-YC7554 | Anti-RSV Neutralizing Antibody (V3S-0522-YC7554) | RSV | Respiratory syncytial virus (RSV) | WB; ELISA; Neut; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0522-YC7555 | Anti-RSV Neutralizing Antibody (V3S-0522-YC7555) | RSV | Respiratory syncytial virus (RSV) | WB; ELISA; Neut; FuncS | Neutralizing/Blocking Antibodies |
| V3S-0522-YC8055 | Anti-IL13 Neutralizing Antibody (V3S-0522-YC8055) | IL13 | Human | ELISA; WB; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC8082 | Anti-MS4A1 Neutralizing Antibody (V3S-0522-YC8082) | MS4A1 | Human | WB; ELISA; IF; FuncS; Apop; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC8122 | Anti-IBV HA Neutralizing Antibody (V3S-0522-YC8122) | IBV HA | Influenza B virus (IBV) | WB; ELISA; Neut | Neutralizing/Blocking Antibodies |
| V3S-0522-YC8225 | Recombinant Anti-CA9 Antibody (V3S-0522-YC8225) | CA9 | Human | WB; FuncS | |
| V3S-0822-YC711 | Anti-Cd36 Neutralizing Antibody (V3S-0822-YC711) | Cd36 | Rat | ELISA; IP; FC; IHC; Neut | Neutralizing/Blocking Antibodies |
| V3S-0822-YC1351 | Anti-IFNB1 Neutralizing Antibody (V3S-0822-YC1351) | IFNB1 | Human | WB; ELISA; Neut | Neutralizing/Blocking Antibodies |
| V3S-0822-YC2567 | Anti-TNFSF4 Neutralizing Antibody (V3S-0822-YC2567) | TNFSF4 | Human | FC; IHC; IHC-Fr; CyTOF; Neut | Neutralizing/Blocking Antibodies |
Read More Close
HOT TARGETS
PDCD1
HIV1 gp120
CD33
IAV HA
PRNP
TNF
MS4A1
CD274
APP
EGFR
CD40
ERBB3
TFPI
ERBB2
SARS-CoV S
PCSK9
MET
BSG
HAVCR2
IL6
CD3
LAG3
ROR1
TNFRSF4
IL33
CD19
CD38
JAG1
IL17A
IFNG
CD47
HCV E2 Protein
IL1A / IL1B
HBsAg
IGF1R
CD4
AXL
ANGPT2
IL23A
NGF
MUC1
TNFRSF18
TNFRSF9
MSTN
IL1B
HRSV F Protein
KDR
SORT1
C5
VEGF
CXCR4
TNFRSF17
Tau
TFRC
CTLA4
IL13
IAV H5N1 HA
TSLP
MSLN
SOST
For research use only, not directly for clinical use.
